Seven Principles Toward Accountable Care in Radiation Oncology

National Cancer Policy Forum Institute of Medicine October 8, 2012

Justin Bekelman, MD




Disclosures

- National Radiation Oncology Registry
- NCI, ACS, philanthropic funding

- Move beyond fee-for-service payment, separating cancer specialists' incomes from treatment choices
 - Technical and professional reimbursement

Adoption of Advanced Radiotherapy Technology Is Rapid and Costly

Substitution of IMRT for 3DCRT Adoption of Brachytherapy
In Prostate Cancer In Breast Cancer




Between 2002 and 2005, > \$1 Bn estimated additional direct costs associated with IMRT for prostate cancer

Source: SEER-Medicare analyses: Yeboa DN (2009); Smith GL (2010), Nyugen P (2011)




Reimbursement Policy and Practice Setting Influence Adoption . . .

Adoption of IMRT
In Breast Cancer, by Medicare Carrier
Local Coverage Determination




Adoption of IMRT In Breast Cancer, by Practice Setting



Source: SEER-Medicare analyses: Smith BD (2011)

. . . and Affect Translation of Evidence to Practice


Outpatient Radiation for Bone Metastases from Prostate Cancer, by Practice Setting, 2005 - 2009



Renn Medicine

 Align provider incentives toward patientcentric, coordinated care among cancer specialists and PCPs

Multi-Disciplinary and Fragmented





Source: SEER-Medicare analyses: Skolarus T (2012)

- 3. Link guideline-concordant care to shared savings from global payments
 - Retain patient choice among high quality providers
 - Improve risk adjustment

Two Models of Accountable Care

Modality-Based

Example:

Care pathway or bundled payment for uncomplicated bone metastasis

- Likely feasible
- Limited impact on care coordination

Diagnosis-Based

Example:

Global payment for localized prostate cancer

- 'Cancer Care Groups'
- Requires diagnosis-based panels of surgical, radiation, medical oncologists
- Greater impact on care coordination and linkage to primary care
- Challenging to implement



- 4. Provide feedback to patients, providers and payers through population-based performance measurement of care quality, outcomes and costs
 - Upgrade federally-supported state cancer registries to provide near-real time ascertainment of quality metrics, risk-adjusted outcomes, and costs by linking with claims databases

- Address cancer specialists' and hospital margins with transparency
 - Can high-quality specialists and facilities retain margins while the overall volume of services declines?
 - Transparency promotes market signaling
 - To hospitals
 - To radiation device industry

- 6. Incentivize radiation device industry to invest in evidence generation (with payers and federal/non-federal funders)
 - Fundamental shift in radiation device industry value proposition
 - Implement unique device identification for postmarketing surveillance


Current CER is Limited

Comparison	Prostate	Breast	Lung
3D Conformal vs Conventional	Single RCTObservational studies	• No RCT	 Observational studies
IMRT vs non-	No RCTObservational studies	• 3 RCTs	• No RCT
Proton therapy vs non-Proton therapy	 RCT and prospective registries accruing 	• No RCT	 RCT and prospective registries accruing



Opportunity for Radiation Device Industry to Invest in Evidence Generation

R&D Spend of Leading Companies as Proportion of Sales



7. Pay for innovation when high-quality evidence development is conducted early in product lifecycle

Corollary: Explore differential reimbursement for treatment and coordination complexity*

Illustrative

Radiotherapy complexity

\$\$	\$\$\$	
Lung or prostate stereotactic	Pediatric proton H&N IMRT/proton	
Combined mod	CNS Proton lality protocols	
vary by disease site (, ,	
\$	\$\$	
Prostate proton	CNS 3D/IMRT Pediatric 3D	
Prostate 3D/IMRT		
Breast 3D/IMRT		

*Evidence of value required

Care coordination complexity



- 1. Move beyond fee-for-service payment, separating cancer specialists' incomes from treatment choices
- 2. Align provider incentives toward patient-centric, coordinated care among cancer specialists and PCPs
- Link guideline-concordant care to shared savings from global payments
- 4. Provide feedback to patients, providers and payers through population-based performance measurement of care quality, outcomes and costs
- 5. Address cancer specialists' and hospital margins with transparency
- 6. Incentivize radiation device industry to invest in evidence generation
- Pay for innovation when high-quality evidence development is conducted early in product lifecycle

